Navigation Links
Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate

using Renagel.

With today’s results, Genzyme has concluded that the powder formulation of Renvela dosed three times per day may represent a promising alternative for patients with chronic kidney disease. The company will continue to move ahead aggressively with clinical and regulatory plans for the powder formulation dosed three times per day, and these data will form part of an NDA submission in the first half of 2008.

“We are very pleased with the progress we have made to date in our multi-faceted development program for Renvela, including filing an NDA for patients on dialysis, completing a successful trial in the pre-dialysis population, and demonstrating the effectiveness of the powder formulation dosed three times per day,” said John P. Butler, president, Genzyme Renal. “Results of the once-per-day trial were greatly influenced by the strong phosphorus reduction seen in the Renagel arm, which was superior to that seen in all but one previously conducted clinical trials. While today’s results will not currently support a regulatory filing for once-per-day dosing, they are clinically meaningful and give us confidence that this approach can be effective. We will continue to work with regulatory authorities to design an appropriate clinical plan to gain approval for this dosing regimen.”

About Renvela

Renvela is a buffered form of Renagel, the most-prescribed phosphate binder in the United States. Like Renagel, Renvela is a calcium-free, metal-free, non-absorbed phosphate binder, and will be available as 800mg tablets once approved. A New Drug Application for Renvela is currently under review by the US Food and Drug Administration for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

In April, Genzyme announced that a new clinical trial showed that Renvela significantly reduced serum phosphorus, calcium-phosphorus product and LDL cholesterol in hyperphosphatem
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/22/2014)... VIEW, Calif. , July 22, 2014 /PRNewswire/ ... resonance imaging (MRI) market, Frost & Sullivan recognizes ... for Product Leadership. Siemens Healthcare,s FREEZEit solution, which ... the need for robust and motion-insensitive imaging. The ... boosted the evolution of body MRI imaging in ...
(Date:7/22/2014)... Ariz. , July 22, 2014  A ... of a SynCardia temporary Total Artificial ... Rochester,s Strong Memorial Hospital with the Freedom® portable ... Fontana, a 64-year-old retiree from a ... decades. He managed the condition with medications, an ...
(Date:7/22/2014)... 2014  PuraMed BioScience®, Inc., (OTCBB: PMBS), a ... and healthcare products, announced today that the company ... "We are pleased to sponsor Operation ... and Chairman of PuraMed BioScience. "Research shows that ... experience migraines much more frequently than the general ...
Breaking Medicine Technology:Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 2Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 3Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 4'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 2'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 3PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3
... trial -SOUTH SAN FRANCISCO, Calif., March 30 Hyperion ... II study of HPN-100 for the treatment of urea ... 27th at the 16th Annual Clinical Genetics Meeting of ... M.D., Ph.D., Howard Hughes Medical Institute Investigator and Professor ...
... studied in combination with the most commonly used doses ... in patients with mixed dyslipidemiaORLANDO, Fla., March 29 ... ,s TRILIPIX(R) (fenofibric acid) delayed-release capsules in combination with ... TRILIPIX 135 mg in combination with rosuvastatin calcium ...
Cached Medicine Technology:Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 2Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 3Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 4New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 2New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 3New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 4New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 5
(Date:7/22/2014)... 22, 2014 CyraCom has been ranked ... in the translation and interpreting industry. Released June 2014 ... report titled "The Language Services Market: 2014," also ranked ... world, moving up two spots from 2013. , In ... LSPs that provide interpretation services – a subset of ...
(Date:7/22/2014)... The Muscular Dystrophy Association (MDA) and Jiffy Lube today ... campaign that will raise funds to help save and ... muscle disease. , As part of the campaign, ... centers through Sept. 1, 2014 to make a donation to ... the fight for muscle health. Since 2012, Jiffy Lube has ...
(Date:7/22/2014)... Paul, Minn. (PRWEB) July 22, 2014 ... dental comfort technology, the Restful Jaw ®. The ... the patient’s jaw while minimizing jaw pain, fatigue and ... can experience shorter treatment times when patients do not ... pain. , The Restful Jaw is a vital ...
(Date:7/22/2014)... HealthDay Reporter MONDAY, July 21, 2014 (HealthDay ... asthma appears to offer relief to people with chronic hives ... The prescription drug -- omalizumab (Xolair) -- is already ... approval earlier this year for that use. The current ... dose for a six-month period it seems to be both ...
(Date:7/22/2014)... at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute ... one of the most complex and difficult-to-treat forms ... , Locally advanced pancreatic cancer has the lowest ... cumulative five-year survival rate of only 4 percent ... an option for patients because tumors often involve ...
Breaking Medicine News(10 mins):Health News:CyraCom Ranked Among the World’s Largest Language Service Providers 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 3Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 2Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 3Health News:Asthma Drug May Help Those With Chronic Hives 2Health News:Asthma Drug May Help Those With Chronic Hives 3Health News:Unique study focuses on combined treatment approach for locally advanced pancreatic cancer 2Health News:Unique study focuses on combined treatment approach for locally advanced pancreatic cancer 3
... Health Plans Offer Broader ChoiceEAGAN, Minn., April 13 ... today announced the largest array of individual health plan ... buy health insurance on their own. The new plans ... series of "design your own health plan" sessions, in ...
... 13 The American Heart Association, with support from ... three research centers to study the development and mechanisms ... next four year, the centers will be conducting studies ... help improve outcomes for heart attack and heart failure ...
... 5,000 years ago , , MONDAY, April 13 (HealthDay News) -- ... stomach,s sake," may have been heeded more than 5,000 years ... residues found in wine jars left in the tomb of ... had been steeped in herbs including balm, coriander, mint and ...
... Jean Nordin Evans, DDS, FIND and Dr. Robert Evans, DMD, FIND, FAGD ... new medical center located at Mill Run Plaza. , ... Groton, MA ... visionary, announced today that Groton Wellness Medical Center has opened its doors ...
... beyond mere placebo effect , , MONDAY, April 13 (HealthDay ... a 25 percent less nausea during radiation treatments, a new ... Journal of Pain and Symptom Management , also discounted ... as a placebo than an actual pain reliever. , ...
... 13 The Advertising Council, in partnership,with Autism Speaks, ... public,service advertisements (PSAs) featuring professional golfer Ernie Els, and ... about autism and to urge,parents to learn the early ... in every 150 children. , , ...
Cached Medicine News:Health News:Blue Cross Launches Largest Selection of Individual Plans Available in Minnesota 2Health News:Blue Cross Launches Largest Selection of Individual Plans Available in Minnesota 3Health News:Three Medical Centers Awarded Funds to Study Generation of Cardiac Muscle Cells 2Health News:Pharoah's Wine Jar Yields Medicinal Secrets 2Health News:Pharoah's Wine Jar Yields Medicinal Secrets 3Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 2Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 3Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 4Health News:Wristbands May Lessen Nausea After Radiation 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 3Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 4
Tennant angled tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano angled tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Catalano straight tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson angled tying forceps is long with tying platform 10 mm, serrated handle and polished finish....
Medicine Products: